096 - Ozempic / Running for Depression / The Case of the Baseball Player's Heart

What does the body of evidence say on Ozempic and its impact on diabetes and obesity? Plus: can you trade in your antidepressant for a job, and Chris returns to the hot seat to diagnose a teenage boy who fell during a baseball game! Block 1: (2:22) Ozempic/Wegovy: GLP-1 receptor agonists; the difference between them; Mounjaro; Trulicity; diabetes biology; glucagon-like peptides 1 and 2; the problem with GLP-1; DPP4 inhibitors Block 2: (12:33) Ozempic/Wegovy: The venom of the Gila monster; how semaglutide became a blockbuster drug; weight loss; the numerous clinical trials; the impact on the stock prices of dialysis companies; downsides; the Internet craze Block 3: (27:03) Is running as beneficial for depression as medication? Block 4: (36:42) The case of the baseball player’s heart   * Jingle by Joseph Hackl * Theme music: “Fall of the Ocean Queen“ by Joseph Hackl * Assistant researcher: Aigul Zaripova   To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/. To make a one-time donation to our show, you can now use PayPal! https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Patrons get a bonus show on Patreon called “Digressions”! Check it out!   References: 1) History of GLP-1 receptor agonists: https://www.statnews.com/2023/09/30/weight-loss-ozempic-nobel-prize-science/ 2) Liraglutide vs. exenatide: https://doi.org/10.1016/S0140-6736(12)61267-7 3) Meta-analysis of GLP-1 receptor agonists: https://doi.org/10.1111/dom.12849 4) A brief summary of the SUSTAIN studies, all 11 of them, which demonstrated the efficacy of semaglutide and its cardiovascular benefit: https://diabetes.medicinematters.com/semaglutide/type-2-diabetes/a-quick-guide-to-the-sustain-trials/12206922 5) A brief summary of the STEP trials, all 10 of them, which tested semaglutide as a weight loss medications even in non-diabetics: https://diabetes.medicinematters.com/semaglutide/obesity/quick-guide-step-trials/18854832 6) Announcement that the FLOW trial is being stopped prematurely: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166327 & https://www.investors.com/news/technology/novo-nordisk-stock-pops-after-hinting-weight-loss-drug-treats-kidney-disease/ 7) GI side effects of GLP-1 receptor agonists: https://doi.org/10.1001/jama.2023.19574 8) Gid M-K’s Slate article: https://slate.com/technology/2023/10/exercise-depression-anxiety-treatment-effectiveness-ssris-research.html 9) Study on running to treat depression: https://www.sciencedirect.com/science/article/pii/S0165032723002239?via%3Dihub#s0065:~:text=https%3A//doi.org/10.1016/j.jad.2023.02.064 10) Details on the DEA-Quebec app to find an AED near you: https://www.jacquesdechamplain.com/en/major-update-to-the-dea-quebec-application/ 11) Government of Canada’s definition of a pesticide: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/environmental-contaminants/human-biomonitoring-resources/glyphosate-in-people.html   It’s Not Twitter, But It’ll Do: 1) Jonathan’s article on how natural health products and dietary supplements are regulated: https://www.mcgill.ca/oss/article/critical-thinking-health-and-nutrition/false-reassurance-dietary-supplement-regulation 2) Jonathan’s article on fentanyl: https://www.mcgill.ca/oss/article/medical-critical-thinking/you-wont-die-touching-fentanyl 3) Chris’ article in Medscape about the COSMOS study: https://www.medscape.com/viewarticle/996926 4) Chris’ Gazette article on coated vs. uncoated aspirin: https://montrealgazette.com/opinion/columnists/christopher-labos-the-bare-facts-about-coated-aspirin